Woolard, Jeanette - University of Nottingham

个人简介

I obtained a first class Honours BSc. degree in Life Sciences (1997) and an MSc in Cardiovascular Pharmacology (1999) from Queen's University, Canada. Subsequently, I moved to the UK to undertake PhD studies with Professors Terry Bennett and Sheila Gardiner at the University of Nottingham. During this time, I was introduced to their novel in vivo cardiovascular model that allows simultaneous monitoring of blood flow velocity in three different vascular beds in a whole-model system, whilst also continuously monitoring mean arterial pressure and heart rate. My interests in drug discovery and the power of integrative pharmacological approaches were stimulated by these early investigations of the cardiovascular effects of sibutramine that were undertaken in collaboration with Knoll Pharmaceuticals Ltd. I was awarded my PhD from the University of Nottingham in 2002. Immediately thereafter, I moved to the Microvascular Research Laboratories at the University of Bristol to undertake postdoctoral work with Professor David Bates on the role of vascular endothelial growth factor (VEGF-A) splice variants in angiogenesis. This led to a seminal publication in Cancer Research in 2004 on the role of VEGF165b as a potential inhibitory VEGF-A splice variant. During this period, my research became focussed on the molecular mechanisms by which VEGF-A splicing could be regulated. This work helped me to secure a Wellcome Trust Advanced Fellowship that I held from 2007 until 2009. In September 2010, following the retirements of both Professor Gardiner and Professor Bennett, I returned to Nottingham to take up a Lectureship in Cardiovascular Pharmacology and to undertake the daunting task of succeeding Sheila Gardiner in the running of the Haemodynamics Laboratory at a time when it was heavily underpinning the in vivo aspects of a major £3M Wellcome Trust Seeding Drug Discovery (SDD) programme. I was promoted to Associate Professor in Cardiovascular Pharmacology in 2015. Over the last six years, I have established the Haemodynamics Laboratory as a major asset for Drug Discovery in Nottingham, delivered the SDD programme and have attracted major funding from Heptares Therapeutics and AstraZeneca. I have maintained my interests in VEGF and have successfully established independent research programmes investigating the molecular pharmacology of VEGF receptor function and the cardiovascular consequences of VEGF receptor inhibition.

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

SOAVE M, STODDART LA, BROWN A, WOOLARD J and HILL SJ, 2016. Use of a new proximity assay (NanoBRET) to investigate the ligand-binding characteristics of three fluorescent ligands to the human β1-adrenoceptor expressed in HEK-293 cells. Pharmacology research & perspectives. 4(5), e00250 CARTER, J. J. and WOOLARD, J., 2015. THE CHRONIC HYPERTENSIVE ACTIONS OF VANDETANIB AND PAZOPANIB IN VIVO JOURNAL OF VASCULAR RESEARCH. 52, 28-28 CARTER JJ, WHEAL AJ, HILL SJ and WOOLARD J, 2015. Effects of receptor tyrosine kinase inhibitors on VEGF165 a- and VEGF165 b-stimulated gene transcription in HEK-293 cells expressing human VEGFR2. British journal of pharmacology. 172(12), 3141-50 VAN UNEN J, WOOLARD J, RINKEN A, HOFFMANN C, HILL SJ, GOEDHART J, BRUCHAS MR, BOUVIER M and ADJOBO-HERMANS MJ, 2015. A Perspective on Studying G-Protein-Coupled Receptor Signaling with Resonance Energy Transfer Biosensors in Living Organisms. Molecular pharmacology. 88(3), 589-95 HUTCHINGS, CATHERINE J., CSEKE, GABRIELLA, OSBORNE, GREG, WOOLARD, JEANETTE, ZHUKOV, ANDREI, KOGLIN, MARKUS, JAZAYERI, ALI, PANDYA-PATHAK, JAHNAVI, LANGMEAD, CHRISTOPHER J., HILL, STEPHEN J., WEIR, MALCOLM and MARSHALL, FIONA H., 2014. Monoclonal anti-beta(1)-adrenergic receptor antibodies activate G protein signaling in the absence of beta-arrestin recruitment MABS. 6(1), 246-261 HILL, STEPHEN J., MAY, LAUREN T., KELLAM, BARRIE and WOOLARD, JEANETTE, 2014. Allosteric interactions at adenosine A(1) and A(3) receptors: new insights into the role of small molecules and receptor dimerization BRITISH JOURNAL OF PHARMACOLOGY. 171(5), 1102-1113 HILL SJ, MAY LT, KELLAM B and WOOLARD J, 2014. Allosteric interactions at adenosine A(1) and A(3) receptors: new insights into the role of small molecules and receptor dimerization. British journal of pharmacology. 171(5), 1102-13 WOOLARD, J., VOUSDEN, W., MOSS, S.J., KRISHNAKUMAR, A., GAMMONS, M.V.R., NOWAK, D.G., DIXON, N., MICKLEFIELD, J., SPANNHOFF, A., BEDFORD, M.T., GREGORY, M.A., MARTIN, C.J., LEADLAY, P.F., ZHANG, M.Q., HARPER, S.J., BATES, D.O. and WILKINSON, B., 2011. Borrelidin modulates the alternative splicing of VEGF in favour of anti-angiogenic isoforms Chemical Science. 2(2), 273-278 HALE, TABEN M, BUSHFIELD, TERRI L, WOOLARD, JEANETTE, PANG, JUDY J, REES-MILTON, KAREN J and ADAMS, MICHAEL A, 2010. Changes critical to persistent lowering of arterial pressure in spontaneously hypertensive rat occur early in antihypertensive treatment. Journal of hypertension. NOWAK, D.G., AMIN, E.M., RENNEL, E.S., HOAREAU-AVEILLA, C., GAMMONS, M., DAMODORAN, G., HAGIWARA, M., HARPER, S.J., WOOLARD, J., LADOMERY, M.R. and BATES, D.O., 2010. Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis Journal of Biological Chemistry. 285(8), 5532-5540 WOOLARD, JEANETTE, BEVAN, HEATHER S, HARPER, STEVEN J and BATES, DAVID O, 2009. Molecular diversity of VEGF-A as a regulator of its biological activity. Microcirculation (New York, N.Y. : 1994). 16(7), 572-92 NOWAK, D.G., WOOLARD, J., AMIN, E.M., KONOPATSKAYA, O., SALEEM, M.A., CHURCHILL, A.J., LADOMERY, M.R., HARPER, S.J. and BATES, D.O., 2008. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors Journal of Cell Science. 121(20), 3487-3495 RENNEL, E.S., WAINE, E., GUAN, H., SCHÜLER, Y., LEENDERS, W., WOOLARD, J., SUGIONO, M., GILLATT, D., KLEINERMAN, E.S., BATES, D.O. and HARPER, S.J., 2008. The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice British Journal of Cancer. 98(7), 1250-1257 WOOLARD, JEANETTE, BENNETT, TERENCE, DUNN, WILLIAM R, HEAL, DAVID J, ASPLEY, SUSAN and GARDINER, SHEILA M, 2004. Acute cardiovascular effects of sibutramine in conscious rats. The Journal of pharmacology and experimental therapeutics. 308(3), 1102-10 WOOLARD, JEANETTE, WANG, WEN-YING, BEVAN, HEATHER S, QIU, YAN, MORBIDELLI, LUCIA, PRITCHARD-JONES, ROWAN O, CUI, TAI-GEN, SUGIONO, MARTO, WAINE, ELIZABETH, PERRIN, RACHEL, FOSTER, REBECCA and DIGBY-BELL,, 2004. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer research. 64(21), 7822-35 WOOLARD, JEANETTE, HALE, TABEN M, BUSHFIELD, TERRI L and ADAMS, MICHAEL A, 2003. Persistent lowering of arterial pressure after continuous and intermittent therapy. Journal of hypertension. 21(4), 813-20 HUTCHINGS CJ, CSEKE G, OSBORNE G, WOOLARD J, ZHUKOV A, KOGLIN M, JAZAYERI A, PANDYA-PATHAK J, LANGMEAD CJ, HILL SJ, WEIR M and MARSHALL FH, 1. Monoclonal anti-β1-adrenergic receptor antibodies activate G protein signaling in the absence of β-arrestin recruitment. mAbs. 6(1), 246-61